{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:34:36Z","timestamp":1793169276508,"version":"4.5.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Traditional pathological markers remain relevant in prognostic assessment for solid tumors, but their clinical value may differ according to tumor biological context. This study evaluated the prognostic significance of Ki-67, histological grade, and vascular invasion (VI) in breast and colorectal cancer, with emphasis on subtype-specific differences. This single-center retrospective cohort included 846 patients with breast cancer or colorectal cancer who underwent curative-intent surgery between 2015 and 2022. Ki-67 expression, histological grade, and VI were extracted from pathological records. The pooled analysis was designed as an exploratory cross-cancer comparison of shared pathological features rather than as an assumption of biological equivalence between the 2 malignancies; cancer-specific and molecular-context analyses were therefore emphasized. Overall survival was assessed using Cox proportional hazards regression, with subgroup analyses according to breast cancer surrogate molecular subtype and colorectal cancer mismatch repair status. A simple Ki-67\/VI score was explored for risk stratification. In multivariable analysis, increased age, stage III disease, high Ki-67 expression, and VI were independently associated with worse overall survival, whereas histological grade was not retained as an independent predictor. In breast cancer, the prognostic effect of Ki-67 was evident in luminal B and triple-negative subtypes but not in luminal A disease. In colorectal cancer, VI showed stronger prognostic value in proficient mismatch repair tumors than in deficient mismatch repair tumors. The combined Ki-67\/VI score provided incremental prognostic stratification and showed better discriminatory performance than any single marker alone. Ki-67 and VI were associated with prognosis in this retrospective cohort, and the magnitude of these associations varied according to tumor biological context. The Ki-67\/VI score should be regarded as exploratory and hypothesis-generating pending internal optimism correction and external validation. Interpretation of conventional pathological indicators should therefore remain cancer- and subtype-specific.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050646","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:08:15Z","timestamp":1789142895000},"page":"e50646","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Subtype-dependent prognostic significance of Ki-67, histological grade, and vascular invasion in breast and colorectal cancer"],"prefix":"10.1097","volume":"105","author":[{"given":"Hongyan","family":"Ji","sequence":"first","affiliation":[{"name":"Jiande First People\u2019s Hospital, Jiande, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binzheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Jiande First People\u2019s Hospital, Jiande, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Xie","sequence":"additional","affiliation":[{"name":"Jiande First People\u2019s Hospital, Jiande, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261028","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jamaoncol.2023.4837","article-title":"Global stage distribution of breast cancer at diagnosis: a systematic review and meta-analysis.","volume":"10","author":"Benitez Fuentes","year":"2024","journal-title":"JAMA Oncol"},{"key":"R2-20261028","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2214\/AJR.20.25223","article-title":"Breast cancer staging: updates in the AJCC cancer staging manual, 8th edition, and current challenges for radiologists, from the AJR special series on cancer staging.","volume":"217","author":"Teichgraeber","year":"2021","journal-title":"AJR Am J Roentgenol"},{"key":"R3-20261028","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/cac2.12639","article-title":"The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update.","volume":"45","author":"Wang","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"R4-20261028","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1038\/s41418-021-00823-x","article-title":"Ki-67 gene expression.","volume":"28","author":"Uxa","year":"2021","journal-title":"Cell Death Differentiation"},{"key":"R5-20261028","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10549-022-06519-1","article-title":"Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?","volume":"192","author":"Choi","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"R6-20261028","first-page":"e69820","article-title":"Expression of Ki-67 in invasive breast carcinoma and its correlation with different clinicopathological features.","volume":"16","author":"Sandilya","year":"2024","journal-title":"Cureus"},{"key":"R7-20261028","doi-asserted-by":"crossref","first-page":"841","DOI":"10.15537\/1658-3175.5596","article-title":"A clinicopathologic study of Ki-67 proliferation index in colorectal carcinoma.","volume":"33","author":"Ahmed","year":"2012","journal-title":"Saudi Med J"},{"key":"R8-20261028","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12885-021-08108-9","article-title":"Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.","volume":"21","author":"Zhuang","year":"2021","journal-title":"BMC Cancer"},{"key":"R9-20261028","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-025-07718-2","article-title":"Exploring the nottingham classification: assessing gene expression profiles in breast cancer patients and their association with outcomes.","volume":"212","author":"Freitas","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"R10-20261028","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12885-022-09193-0","article-title":"Lympho-vascular invasion impacts the prognosis in breast-conserving surgery: a systematic review and meta-analysis.","volume":"22","author":"Zhong","year":"2022","journal-title":"BMC Cancer"},{"key":"R11-20261028","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/jcu.23300","article-title":"Is there a potential biomarker in distinguishing invasive breast carcinomas with elevated Ki-67 levels among 2D-SWE, SMI, and 18F-FDG PET-CT\/MRI-derived parameters?: a single-center data.","volume":"51","author":"Kurt","year":"2023","journal-title":"J Clin Ultrasound"},{"key":"R12-20261028","doi-asserted-by":"crossref","first-page":"23.e5","DOI":"10.1016\/j.urolonc.2023.11.001","article-title":"Assessment of Ki-67 proliferation index in prognosis prediction in patients with nonmetastatic clear cell renal cell carcinoma and tumor thrombus.","volume":"42","author":"Zhao","year":"2024","journal-title":"Urol Oncol"},{"key":"R13-20261028","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1007\/s00464-015-4735-3","article-title":"The Ki-67 labeling index and lymphatic\/venous permeation predict the metastatic potential of rectal neuroendocrine tumors.","volume":"30","author":"Sugimoto","year":"2016","journal-title":"Surg Endosc"},{"key":"R14-20261028","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00000658-200201000-00003","article-title":"Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years.","volume":"235","author":"Mirza","year":"2002","journal-title":"Ann Surg"},{"key":"R15-20261028","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/his.13404","article-title":"The value of intramural vascular invasion in colorectal cancer","volume":"72","author":"Knijn","year":"2018","journal-title":"Histopathology"},{"key":"R16-20261028","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/nan.12185","article-title":"Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases.","volume":"41","author":"Berghoff","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"key":"R17-20261028","doi-asserted-by":"crossref","first-page":"1959341","DOI":"10.1080\/15321819.2021.1959341","article-title":"Immunohistochemical expression of FOXP3 in gastric carcinoma; its relation to Ki-67 proliferation marker, HER2\/neu expression, and other clinicopathological parameters.","volume":"43","author":"Abd-Allah","year":"2022","journal-title":"J Immunoassay Immunochem"},{"key":"R18-20261028","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10549-019-05402-w","article-title":"Ki-67 (30-9) scoring and differentiation of luminal a- and luminal b-like breast cancer subtypes.","volume":"178","author":"Viale","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"R19-20261028","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1080\/01443615.2022.2037124","article-title":"Clinical significance of CD34, podoplanin and Ki-67 expression in patients with locally advanced squamous cell cervical carcinoma.","volume":"42","author":"Kubik","year":"2022","journal-title":"J Obstet Gynaecol"},{"key":"R20-20261028","doi-asserted-by":"crossref","first-page":"107976","DOI":"10.1016\/j.dib.2022.107976","article-title":"Optimized gating strategy and supporting flow cytometry data for the determination of the Ki-67 proliferation index in the diagnosis of myelodysplastic syndrome.","volume":"41","author":"Mestrum","year":"2022","journal-title":"Data Brief"},{"key":"R21-20261028","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.humpath.2018.07.007","article-title":"Histomorphometric evaluation of the Ki-67 proliferation rate and CD34 microvascular and D2-40 lymphovascular densities drives the pulmonary typical carcinoid outcome.","volume":"81","author":"de Vilhena","year":"2018","journal-title":"Hum Pathol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:01:01Z","timestamp":1793167261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":21,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050646","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"2026-04-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}